Main Article Content
the optimized formulation based on the pharmacokinetics of carvedilol. Matrix tablets each containing 80 mg of carvedilol were formulated employing PEO N60 K, PEO 301, and PEO 303 as release-retarding polymers and Î² Cyclodextrin and
HP Î² cyclodextrin as release modulators from the matrix. Carvedilol release from the formulated tablets was very slow. Hence the release was modulated with the use of cyclodextrins. The dissolution from the matrix tablets was spread over
more than 24 hours and depended on the type of polymer, its concentration and the type of cyclodextrin used. All the matrix tablets prepared using polyethylene oxides showed very good controlled release over more than 24 hours.The matrix tablets prepared using HP Î² cyclodextrin showed a higher dissolution rate and gave a dissolution profile that was comparable to the theoretical sustained release needed for once-a-day administration of carvedilol. The drug release mechanism from the matrix tablets was found to be quasi Fickian mechanism.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
Ruffolo RR Jr, Feuerstein GZ. Pharmacology of carvedilol: Rational for
use in hypertension, coronary artery disease, and congestive heart
failure. Cardiovasc Drugs Ther 1997:11:247-56.
Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. The
pharmacology of carvedilol Eur J Clin Pharmacol 1990;38:S82-8.
McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: A review of
its pharmacodynamic and pharmacokinetic properties and therapeutic
efficacy. Drugs 1993;45:232-58.
Apicella A, Cappello B, Del Nobile MA, La Rotonda MI, Mensitieri G,
Nicolais L. Poly (ethylene oxide) (PEO) and different molecular
weight PEO blends monolithic devices for drug release. Biomaterials
Zhang F, McGinity JW. Properties of sustained-release tablets prepared
by hot-melt extrusion. Pharm Dev Technol 1999;4:241-50.
Razaghi AM, Schwartz JB. Investigation of Cyclobenzaprine HCl Release
from Oral Osmotic Delivery Systems Containing a Water-Swellable
Polymer. Drug Dev Ind Pharm 2002;28:631-9.
Jamzad S, Fassihi R. Development of a controlled release low dose
class II drug-Glipizide. Int J Pharm 2006;312:24-32.
Wagner JG, Nelson E. Percent absorbed time plots derived from blood
level and/or urinary excretion data. J Pharm Sci 1963;52:610-1.
Rudnic, EM, Kottke MK. Tablet Dosage Forms. In: Modern Pharmaceutics.
Banker GS, Rhodes CT, editors. 3rd ed. New York: Marcel Dekker, Inc;
Higuchi T. Mechanism of sustained action medication: Theoretical
analysis of rate of release of solid drugs dispersed in solid matrices Pharm Sci 1963;52:1145-9.
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanism
of solute release from porous hydrophilic polymers. Int J Pharma
Basak SC, Jayakumar Reddy BM, Lucas Mani KP. Formulation and release
behaviour of sustained release ambroxol hydrochloride HPMC matrix
tablet. Indian J Pharm Sci 2006;68:594-8.